- One Health
- Pain Management
- Oncology
- Geriatric & Palliative Medicine
- Ophthalmology
- Anatomic Pathology
- Poultry Medicine
- Infectious Diseases
- Dermatology
- Theriogenology
- Nutrition
- Animal Welfare
- Radiology
- Internal Medicine
- Small Ruminant
- Cardiology
- Dentistry
- Feline Medicine
- Soft Tissue Surgery
- Urology/Nephrology
- Avian & Exotic
- Preventive Medicine
- Anesthesiology & Pain Management
- Integrative & Holistic Medicine
- Food Animals
- Behavior
- Zoo Medicine
- Toxicology
- Orthopedics
- Emergency & Critical Care
- Equine Medicine
- Pharmacology
- Pediatrics
- Respiratory Medicine
- Shelter Medicine
- Parasitology
- Clinical Pathology
- Virtual Care
- Rehabilitation
- Epidemiology
- Fish Medicine
- Diabetes
- Livestock
- Endocrinology
Aratana Therapeutics receives FDA approval of canine appetite stimulus
Entyce is a first-of-its-kind therapeutic for inappetent dogs.
Images courtesy of Aratana TherapeuticsAratana Therapeutics Inc. has received approval from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) of Entyce-a first-of-its-kind ghrelin receptor agonist that stimulates appetite in dogs-according to a company release.
Entyce, a new chemical entity, works by mimicking the hunger hormone ghrelin to stimulate appetite. The prescription medication is a flavored liquid that is administered orally.
“Nearly 10 million dogs are diagnosed with inappetence each year and we believe Entyce will fulfill a significant unmet need to stimulate appetite in dogs,” says Steven St. Peter, MD, president and chief executive officer of Aratana Therapeutics, in the release. Aratana is reportedly planning a February 2017 commercial launch of Entyce in order to coincide with the North American Veterinary Conference.
